Details for Patent: 10,004,717
Which drugs does patent 10,004,717 protect, and when does it expire?
Patent 10,004,717 protects QBREXZA and is included in one NDA.
This patent has twenty-eight patent family members in thirteen countries.
Summary for Patent: 10,004,717
| Title: | Glycopyrrolate salts | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | Salts of glycopyrrolate, including solid forms and formulations such as topicals thereof, are disclosed. Methods of making glycopyrrolate salts, including formulations such as topicals thereof, and methods of treating hyperhidrosis with salts of glycopyrrolate, and formulations such as topicals thereof, are disclosed. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | John Allan STATLER, Anthony Adrian SHAW, Delphine Caroline Imbert, Jennifer Leigh NELSON, Patricia Andres, Lisa Lynn McQueen, Stephan Xander Mattheus BOERRIGTER, Jon Gordon Selbo, Mark Christopher Andres | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Journey Medical Corp | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US15/438,636 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,004,717 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Formulation; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | US Patent 10,004,717: Glycopyrrolate Tosylate Solution, Qbrexza Formulation, and Patent LandscapeUS Patent 10,004,717 protects a narrow topical glycopyrrolate tosylate formulation and defined methods and packaging for treating hyperhidrosis. Its strongest commercial coverage is directed to the Qbrexza-type premoistened cloth containing approximately 2.4% glycopyrronium tosylate, citrate buffer, approximately 58% ethanol, and an absorbent polypropylene pad. The patent does not broadly cover every glycopyrrolate product or every topical anticholinergic formulation. The patent issued June 26, 2018, from a Dermira-related patent family with a nominal patent-term endpoint in January 2034. The principal commercial risk is an ANDA applicant attempting to design around the exact solvent, buffer, concentration, pH, or packaging limitations while pursuing a Paragraph IV certification against any Orange Book listing. What does US Patent 10,004,717 protect?The patent has four substantive protection groups:
The patent is formulation-centered. The claims do not cover glycopyrrolate as a molecule in the abstract. They require a particular salt form and a defined composition. What are the key limitations of independent claim 1?Claim 1 requires all of the following:
A competing product outside any required limitation should not literally infringe claim 1, subject to claim construction and the doctrine of equivalents. Active ingredient and salt limitationThe claim is directed to glycopyrrolate tosylate, not merely glycopyrrolate or glycopyrronium bromide. A product using a different counterion, such as bromide or chloride, would have a strong noninfringement position against the literal salt limitation. The claim also recites the specific racemic mixture of two diastereomeric species. A product using a substantially different stereochemical composition, a purified enantiomer, or another salt form could avoid literal infringement. The strength of that design-around depends on whether the alternative product is treated as equivalent under the doctrine of equivalents. Ethanol limitationThe 57%-59.5% dehydrated ethanol range is one of the most commercially significant limitations. A formulation containing less than 57% or more than 59.5% ethanol may avoid literal infringement of claim 1. The word "about" creates a claim-construction issue. Courts would assess the scope of "about" using the specification, analytical precision, formulation tolerances, and prosecution history. A generic manufacturer could target ethanol outside the claimed range, but changing ethanol content may affect drying time, delivery through a cloth, skin tolerability, preservative performance, and drug loading. Buffer limitationClaim 1 requires both approximately 0.15% anhydrous citric acid and approximately 0.06% sodium citrate dihydrate. Claims 11-16 broaden certain dependent formulations to citrate buffering and defined pH ranges, but they remain dependent on claim 1's core composition. A formulation buffered with phosphate, acetate, lactate, or another system could present a design-around route. Removing one citrate component may also be relevant, although the analysis would depend on whether the resulting formulation still falls within the claim's "about" ranges. pH limitationThe independent claim covers pH 3.5-5.5. Dependent claims narrow the range to:
The pH measurement temperature matters for claim 16 and claim 17. A product tested at a different temperature could generate an analytical dispute, although the specification and ordinary laboratory practice would inform the interpretation. How do claims 2 through 9 divide the glycopyrrolate concentration?Claims 2-9 create overlapping concentration positions:
Claims 7 and 26 are particularly relevant to the marketed Qbrexza configuration because they identify approximately 2.4% glycopyrrolate tosylate. Claims 8 and 18 separately cover approximately 2.5%, with claim 18 adding approximately pH 4.5. The claims use overlapping ranges rather than a single concentration. This gives the patent multiple fallback positions if a court narrows the broad 1%-6% range or finds one range vulnerable to prior art. What formulations are protected by US 10,004,717?The principal claimed formulation is an aqueous, ethanol-containing topical solution. The claim architecture protects a composition with a particular balance of:
Claim 10 adds povidone as a binding agent and a butyl ester of a polyvinylmethylether/maleic anhydride acid copolymer as a film-forming agent. This claim is narrower and is directed to formulations with film-forming or adhesion-related excipients. Claim 17 requires the formulation to be clear and colorless or pale yellow at pH 4.0-5.0 at 25°C. That limitation may be useful against a product that otherwise copies the formulation but has visible precipitation, substantial color, or a different physical profile. What does the patent protect about Qbrexza?Qbrexza is a topical glycopyrronium tosylate product approved by the FDA for primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older. It is supplied as a premoistened cloth containing glycopyrronium tosylate, commonly described as 2.4% w/w glycopyrronium tosylate. The product is administered once daily to the axilla. FDA approval occurred in June 2018 under NDA 212333. [1] The claims most closely aligned with the commercial product are:
The commercial product may be described in FDA labeling using glycopyrronium terminology, while the patent claims use glycopyrrolate terminology. The terms refer to the same active anticholinergic moiety in different nomenclature contexts. What is the Orange Book status of US 10,004,717?US Patent 10,004,717 has been associated with the Qbrexza regulatory and patent estate and is relevant to Orange Book-based generic entry analysis. The Orange Book listing controls the statutory notification framework for an ANDA applicant that references the NDA. The relevant certification options are:
For a listed formulation, method-of-use, or drug-product patent, a Paragraph IV notice can trigger patent litigation under the Hatch-Waxman Act. The 45-day period following receipt of a Paragraph IV notice is central to the potential 30-month stay of FDA approval. [2] Orange Book status can change through patent listing updates, delisting, corrections, patent expiration, or regulatory changes. The patent's presence in the patent family does not by itself establish that every claim remains enforceable or that every claim covers the commercial product. When does US Patent 10,004,717 lose exclusivity?The patent has a nominal expiration in January 2034 based on the patent family's January 2014 nonprovisional filing and January 2013 priority history. The exact enforceable expiration should be calculated from the patent's term-adjustment data and any terminal disclaimer appearing in the official patent record. [3]
Patent expiry does not automatically create immediate generic launch. A generic applicant may launch after a successful Paragraph IV outcome, a settlement date, patent expiration, or another legally available pathway. FDA regulatory exclusivity and patent exclusivity are separate rights. What generic entry risks exist?A generic or authorized-generic applicant could pursue several design-around strategies. Formulation design-aroundsPotential design-around variables include:
Each change can affect product performance and may encounter separate patents or regulatory comparability requirements. Product-by-process and product-performance risksThe patent is not limited solely to a chemical composition. Its claims reach the delivery article and packaging. A product using the same solution on a different pad may avoid claims 27-31 but could remain exposed to claims 1-18 and 26. Conversely, a product using a similar pad but a different solution may avoid the composition claims while potentially raising questions under the method claims if the administered formulation still falls within claim 1. Method-of-use limitationsClaims 19-25 cover topical treatment of hyperhidrosis. Claims 21-24 identify axilla, hands, feet, groin, face, back, and abdomen. A generic product label directed to hyperhidrosis can increase method-claim exposure, especially if the labeling instructs use in the claimed body areas. A label limited to an unclaimed indication does not necessarily eliminate infringement risk if the product is marketed for an infringing use or the relevant use is reasonably foreseeable, but inducement analysis depends on the totality of the labeling and conduct. How strong is the patent estate?US 10,004,717 has meaningful commercial strength but narrower technical scope than a basic compound patent.
The most defensible commercial position is likely the combination of formulation and product claims, particularly where an ANDA uses the same active salt, approximately 2.4% loading, similar ethanol concentration, citrate buffer, pH, cloth material, and foil pouch. What invalidity issues could affect the patent?The principal validity issues are likely to involve: AnticipationA challenger could search earlier patents, publications, and product-development documents for a single reference disclosing the full combination of:
Because claim 1 combines several quantitative limitations, a single-reference anticipation case may be difficult unless the exact formulation was previously disclosed. ObviousnessObviousness is a more substantial risk. A challenger could combine references relating to:
The patentee's response would likely rely on formulation stability, skin tolerability, controlled delivery, drying characteristics, unexpected performance, and the particular interaction between solvent, pH, buffer, and concentration. Written description and enablementThe broad ranges in claim 1, particularly 1%-6% active ingredient and 57%-59.5% ethanol, could be tested against the specification's experimental support. The dependent claims provide multiple narrower positions, reducing the practical impact of a challenge to the broadest range. IndefinitenessTerms such as "about," "clear," "pale yellow," and "therapeutically effective amount" can create disputes. These terms are common in pharmaceutical claims, but enforceability depends on whether the specification and ordinary analytical methods provide objective boundaries. What patent litigation and settlement issues matter?A Paragraph IV challenge would likely place the following issues at the center of litigation:
A settlement could establish an agreed generic launch date before the nominal January 2034 expiration. Settlement terms may also address authorized generic supply, limited licenses, product-specific carve-outs, or launch rights under specified conditions. A settlement date does not amend the patent's expiration date and does not necessarily establish claim validity. How does the patent compare with biosimilar and generic competition?Biosimilar risk is not applicable in the ordinary regulatory sense. Glycopyrrolate tosylate is a small-molecule drug, so competition would ordinarily proceed through an ANDA under section 505(j), not a biologics license application under the biosimilar pathway. The relevant competitive products are:
A compounded formulation may not follow the same FDA approval and Orange Book pathway, but it can still create commercial pressure. It may also raise separate issues involving compounding rules, promotional claims, and state pharmacy regulation. What revenue exposure is associated with the patent?The patent's revenue exposure is tied primarily to Qbrexza and the broader prescription treatment market for primary axillary hyperhidrosis. FDA approval limited the initial indication to primary axillary hyperhidrosis, while the patent claims extend to other body areas, including the hands, feet, groin, face, back, and abdomen. The patent protects the product configuration that supports:
Revenue exposure depends on net sales, payer coverage, patient persistence, competing topical products, compounded alternatives, and the timing of generic approval. A successful Paragraph IV challenge could materially compress pricing because the formulation and cloth system are relatively easy for a generic manufacturer to replicate if the regulatory pathway and manufacturing controls are established. Key Takeaways
FAQsDoes US 10,004,717 cover all topical glycopyrrolate products?No. The claims require specific formulation and, in some cases, delivery-system limitations. A topical glycopyrrolate product using another salt, buffer, solvent profile, pH, or dosage form may fall outside the literal claims. Can a generic avoid the patent by changing glycopyrrolate tosylate to glycopyrrolate bromide?A salt substitution creates a strong literal noninfringement argument because the claims specify glycopyrrolate tosylate. The doctrine of equivalents and any separate patent rights would still require analysis. Does the patent cover treatment of palmar or plantar hyperhidrosis?Claims 22 and 23 expressly recite application to the hands and feet. Those claims are narrower than claim 19 but directly address palmar and plantar use. Is the Qbrexza cloth itself patented?The patent claims an absorbent pad containing the solution, including polypropylene and nonwoven 100% polypropylene embodiments. It also claims a pouch with an aluminum-foil laminate layer. Could a generic launch before January 2034?Yes, if it obtains a favorable Paragraph IV outcome, reaches a settlement permitting earlier entry, invalidates or avoids the relevant claims, or qualifies under another legally available pathway. Patent expiration alone is not the only determinant of launch timing. References
More… ↓ |
Drugs Protected by US Patent 10,004,717
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Journey | QBREXZA | glycopyrronium tosylate | CLOTH;TOPICAL | 210361-001 | Jun 28, 2018 | RX | Yes | Yes | 10,004,717 | ⤷ Start Trial | Y | TOPICAL TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,004,717
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2014223172 | ⤷ Start Trial | |||
| Australia | 2016269524 | ⤷ Start Trial | |||
| Canada | 2902795 | ⤷ Start Trial | |||
| China | 105026369 | ⤷ Start Trial | |||
| European Patent Office | 2961734 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
